Skip to content

Axsome Therapeutics

US · AXSM #1533 by market cap Listed 2015
172.97 -1.37 -0.79%
Live - 5344 symbols - heartbeat 8s ago · 2026-10-08 05:31
Pre-market 174.31 +0.77%
After-hours 172.97 0.00%
Overnight 172.59 -0.22%
Market cap
9.06B
P/B
108.79
EPS
-3.68
Reader sentiment Are you bullish or bearish on AXSM?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $251 to $315
    Market Newswire · 2026/8/11
  • Rating change
    BMO Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $310
    Market Newswire · 2026/9/14
  • Rating change
    RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $297
    Market Newswire · 2026/8/11
  • Truist Financial Initiates Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $285
    Market Newswire · 2026/9/23
  • Rating change
    Jefferies Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $380
    Market Newswire · 2026/8/12
  • Rating change
    H.C. Wainwright Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
    TipRanks · 2026/9/22
  • Wells Fargo Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $256
    Market Newswire · 2026/10/1
  • Rating change
    Piper Sandler Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $258
    Market Newswire · 2026/9/18
  • Rating change
    Jefferies Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $380
    Market Newswire · 2026/7/16
  • Deutsche Bank Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $267
    Market Newswire · 2026/9/29
  • Rating change
    Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $316
    Market Newswire · 2026/9/12
  • Rating change
    BMO Capital Initiates Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $310
    Market Newswire · 2026/7/21
  • Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Hold Rating, Maintains Target Price $251
    Market Newswire · 2026/9/25
  • Rating change
    RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $297
    Market Newswire · 2026/9/18
  • Rating change
    Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $306
    Market Newswire · 2026/7/31
  • Rating change
    Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $306
    Market Newswire · 2026/8/4
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL)
    TipRanks · 2026/7/16
  • H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $290
    Market Newswire · 2026/9/25
  • Rating change
    Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $310
    Market Newswire · 2026/7/16
  • Rating change
    Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $316
    Market Newswire · 2026/8/13

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 05:31:53 · For reference only, not investment advice and not tailored to your situation.